Sudan vs Timor-Leste: Average cost of multi drug-resistant tuberculosis treatment
Sudan
51,726 constant 2022 US$
in 2023
Timor-Leste
50,471 constant 2022 US$
in 2024
Sudan rank
1st
Timor-Leste rank
2nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Sudan
- Timor-Leste
How they compare
Sudan currently reports 51,726 constant 2022 US$ against 50,471 constant 2022 US$ in Timor-Leste, a difference of 1,255 constant 2022 US$.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Sudan ahead.
Sudan ranks 1st and Timor-Leste ranks 2nd of 92 countries.
Sudan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Sudan | Timor-Leste | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,275 constant 2022 US$ | 1,816 constant 2022 US$ | 459.33 constant 2022 US$ | Sudan |
| 2020s | 13,796 constant 2022 US$ | 489 constant 2022 US$ | 13,307 constant 2022 US$ | Sudan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Sudan or Timor-Leste?
- Sudan, at 51,726 constant 2022 US$ against 50,471 constant 2022 US$ in Timor-Leste as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Sudan and Timor-Leste?
- 1,255 constant 2022 US$, with Sudan ahead.
- How many years of comparable data are there for Sudan and Timor-Leste?
- 7 years are reported by both, from 2017 to 2023.
- How do Sudan and Timor-Leste rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Sudan ranks 1st and Timor-Leste ranks 2nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.